BAT IT: Banked Anti-SARS Cov-2 T Cell Infusions for Treatment of COVID 19
Latest Information Update: 04 May 2022
At a glance
- Drugs ALVR 109 (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms BATIT
- Sponsors AlloVir
- 16 Dec 2021 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped : due to trial's eligibility criteria and the low census of hospitalized COVID-19 patients meeting eligibility criteria, the Sponsor will be unable to enroll a meaningful number of patients in this single-center trial in a reasonable time frame.
- 03 Nov 2021 Planned End Date changed from 15 Aug 2021 to 15 Jan 2022.
- 03 Nov 2021 Planned primary completion date changed from 15 Aug 2021 to 15 Jan 2022.